Overexpression of TYRO3 indicates poor prognosis and induces gastric cancer progression via AKT‐mTOR pathway

Gastric cancer (GC) is among of the leading causes of cancer mortality worldwide. This is because many patients are diagnosed with advanced GC and postoperative radiotherapy and chemotherapy have also exhibited limited effects on GC. TYRO3 has been considered carcinogenic and a potential therapeutic target for GC. However, TYRO3 function and mechanism in GC remains elusive. The study results indicated that TYRO3 was aberrantly elevated in GC tissues and predicted poor prognosis. TYRO3 is closely associated with clinicopathological indicators in GC tissues such as lymph node metastasis, venous invasion, neural invasion, and the tumor‐node‐metastasis stage. In addition, TYRO3 expression levels are closely related to the AKT‐mTOR pathway in GC tissues. Moreover, the oncogenic role of TYRO3 was determined through in vitro and in vivo functional assays, and knockdown of the TYRO3 expression level in GC cell lines can effectively suppress the AKT‐mTOR pathway and inhibit tumor cell proliferation and migration. In conclusion, this study provides a theoretical basis for establishing the potential association and regulatory mechanism between TYRO3 and AKT‐mTOR and offers a new strategy for GC‐targeted therapy.

[1]  F. Radvanyi,et al.  Tyro3 Targeting as a Radiosensitizing Strategy in Bladder Cancer through Cell Cycle Dysregulation , 2022, International journal of molecular sciences.

[2]  Lizhen Lin,et al.  Saikosaponin B4 suppression cancer progression by inhibiting SW480 and SW620 cells proliferation via the PI3K/AKT/mTOR pathway in colon cancer. , 2022, Current cancer drug targets.

[3]  J. Guh,et al.  The Combination of a Novel GLUT1 Inhibitor and Cisplatin Synergistically Inhibits Breast Cancer Cell Growth By Enhancing the DNA Damaging Effect and Modulating the Akt/mTOR and MAPK Signaling Pathways , 2022, Frontiers in Pharmacology.

[4]  Weigang Zhang,et al.  TBK1 Facilitates GLUT1-Dependent Glucose Consumption by suppressing mTORC1 Signaling in Colorectal Cancer Progression , 2022, International journal of biological sciences.

[5]  Ning Zhang,et al.  S6K1-mediated phosphorylation of PDK1 impairs AKT kinase activity and oncogenic functions , 2022, Nature Communications.

[6]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[7]  Kui-Sheng Chen,et al.  Targeting PI3K/Akt signal transduction for cancer therapy , 2021, Signal Transduction and Targeted Therapy.

[8]  K. Yeoh,et al.  Mapping the genomic diaspora of gastric cancer , 2021, Nature Reviews Cancer.

[9]  K. Hoe,et al.  G-749 Promotes Receptor Tyrosine Kinase TYRO3 Degradation and Induces Apoptosis in Both Colon Cancer Cell Lines and Xenograft Mouse Models , 2021, Frontiers in Pharmacology.

[10]  Xinyu Shao,et al.  The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer , 2021, Frontiers in Oncology.

[11]  S. Hafizi,et al.  Identification of signalling pathways activated by Tyro3 that promote cell survival, proliferation and invasiveness in human cancer cells , 2021, Biochemistry and biophysics reports.

[12]  H. Hua,et al.  Targeting Akt in cancer for precision therapy , 2021, Journal of Hematology & Oncology.

[13]  H. Ji,et al.  PI3K/Akt/mTOR signaling orchestrates the phenotypic transition and chemoresistance of small cell lung cancer. , 2021, Journal of genetics and genomics = Yi chuan xue bao.

[14]  Andee M. Beierle,et al.  Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor , 2021, Translational oncology.

[15]  Jun Yao,et al.  TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. , 2021, The Journal of clinical investigation.

[16]  Joseph Cursons,et al.  The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer , 2021, Nature Communications.

[17]  P. thor Straten,et al.  TAM Receptor Inhibition–Implications for Cancer and the Immune System , 2021, Cancers.

[18]  B. Badgwell,et al.  Current treatment and recent progress in gastric cancer , 2021, CA: a cancer journal for clinicians.

[19]  Jing Wang,et al.  AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors , 2020, Molecular Cancer Research.

[20]  Y. Fujiwara,et al.  Prognostic Significance of TYRO3 Receptor Tyrosine Kinase Expression in Gastric Cancer , 2020, AntiCancer Research.

[21]  T. Han,et al.  Yes-Associated Protein Contributes to Cell Proliferation and Migration of Gastric Cancer via Activation of Gli1 , 2020, OncoTargets and therapy.

[22]  C. Cho,et al.  m6A RNA modification modulates PI3K/Akt/mTOR signal pathway in Gastrointestinal Cancer , 2020, Theranostics.

[23]  H. El‐Serag,et al.  Burden of Gastric Cancer. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  Wei Zhang,et al.  TYRO3 facilitates cell growth and metastasis via activation of the Wnt/β-catenin signaling pathway in human gastric cancer cells , 2020, Aging.

[25]  A. Maimon,et al.  TAM receptors, Phosphatidylserine, inflammation, and Cancer , 2019, Cell Communication and Signaling.

[26]  K. Pienta,et al.  Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment , 2019, Molecular Cancer.

[27]  E. Tindall,et al.  Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor. , 2019, Cancer research.

[28]  Hui Zhang,et al.  GLI1 overexpression promotes gastric cancer cell proliferation and migration and induces drug resistance by combining with the AKT-mTOR pathway. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[29]  Nicolas Stransky,et al.  TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer , 2019, British Journal of Cancer.

[30]  Wei Zhang,et al.  Fatty acid 2-hydroxylation inhibits tumor growth and increases sensitivity to cisplatin in gastric cancer , 2019, EBioMedicine.

[31]  Xiaodong Wang,et al.  The Emerging Role of TYRO3 as a Therapeutic Target in Cancer , 2018, Cancers.

[32]  Ancheng Qin,et al.  MicroRNA-7 inhibits colorectal cancer cell proliferation, migration and invasion via TYRO3 and phosphoinositide 3-kinase/protein B kinase/mammalian target of rapamycin pathway suppression , 2018, International journal of molecular medicine.

[33]  Zhiqiang Ma,et al.  Targeting Gas6/TAM in cancer cells and tumor microenvironment , 2018, Molecular Cancer.

[34]  J. Chien,et al.  Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy , 2018, Front. Pharmacol..

[35]  P. Carmeliet,et al.  Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia , 2016, Clinical Cancer Research.

[36]  S. Tsai,et al.  Targeting TYRO3 inhibits epithelial–mesenchymal transition and increases drug sensitivity in colon cancer , 2016, Oncogene.

[37]  R. Pieters,et al.  Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration. , 2013, Gene.